Wall Street's Bullish Outlook on Intuitive Surgical Amid Challenges
Intuitive Surgical (ISRG) has experienced a significant decline in its stock price this year, with shares down nearly 40% by late July. Despite the poor performance, Wall Street remains overwhelmingly bullish, with 24 out of 32 analysts rating it as a 'buy' or 'strong buy.' The company faces several challenges including slowing growth and increased competition from firms like Johnson & Johnson (JNJ) and Medtronic (MDT), particularly in China where government pricing policies are affecting its market expansion. Other factors impacting Intuitive Surgical include the expiration of ACA subsidies, which is reducing procedure volumes for its da Vinci surgical robots. Additionally, GLP-1 drugs have led to a decline in bariatric procedures using these systems. Despite these headwinds, analysts argue that they do not represent showstoppers and are outweighed by long-term tailwinds such as aging demographics driving demand for robotic surgery. The company's CFO noted the impact of GLP-1 drugs is limited to specific areas like bariatric procedures. Analysts remain optimistic about Intuitive Surgical’s future, citing technological advancements that could expand its market and maintain growth potential.
Tickers: $ISRG $JNJ $MDT $SPGI $SYK
Topics: earnings call healthcare sector Intuitive Surgical market competition robotic surgery